148 related articles for article (PubMed ID: 34979089)
1. A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry
Adam C; Bray TL; Pérez-López AM; Tan EH; Rubio-Ruiz B; Baillache DJ; Houston DR; Salji MJ; Leung HY; Unciti-Broceta A
J Med Chem; 2022 Jan; 65(1):552-561. PubMed ID: 34979089
[TBL] [Abstract][Full Text] [Related]
2. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
3. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
[TBL] [Abstract][Full Text] [Related]
4. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity.
Zhao D; Zhang H; Tao W; Wei W; Sun J; He Z
Biomater Sci; 2017 Feb; 5(3):502-510. PubMed ID: 28116362
[TBL] [Abstract][Full Text] [Related]
5. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Guo X; Lerner-Tung M; Chen HX; Chang CN; Zhu JL; Chang CP; Pizzorno G; Lin TS; Cheng YC
Biochem Pharmacol; 1995 Apr; 49(8):1111-6. PubMed ID: 7748192
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Malet-Martino M; Martino R
Oncologist; 2002; 7(4):288-323. PubMed ID: 12185293
[TBL] [Abstract][Full Text] [Related]
9. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.
Garcia-Sanchez F; Pizzorno G; Fu SQ; Nanakorn T; Krause DS; Liang J; Adams E; Leffert JJ; Yin LH; Cooperberg MR; Hanania E; Wang WL; Won JH; Peng XY; Cote R; Brown R; Burtness B; Giles R; Crystal R; Deisseroth AB
Blood; 1998 Jul; 92(2):672-82. PubMed ID: 9657770
[TBL] [Abstract][Full Text] [Related]
10. The prodrugs of 5-fluorouracil.
Malet-Martino M; Jolimaitre P; Martino R
Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):267-310. PubMed ID: 12678747
[TBL] [Abstract][Full Text] [Related]
11. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
12. Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach.
Weiss JT; Dawson JC; Macleod KG; Rybski W; Fraser C; Torres-Sánchez C; Patton EE; Bradley M; Carragher NO; Unciti-Broceta A
Nat Commun; 2014; 5():3277. PubMed ID: 24522696
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
Shindoh H; Nakano K; Yoshida T; Ishigai M
J Toxicol Sci; 2011 Aug; 36(4):411-22. PubMed ID: 21804305
[TBL] [Abstract][Full Text] [Related]
14. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
[TBL] [Abstract][Full Text] [Related]
15. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
Watabe T; Okuda H; Ogura K
Yakugaku Zasshi; 1997 Nov; 117(10-11):910-21. PubMed ID: 9414600
[TBL] [Abstract][Full Text] [Related]
16. Direct in vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: a magnetic resonance study.
Guerquin-Kern JL; Volk A; Chenu E; Lougerstay-Madec R; Monneret C; Florent JC; Carrez D; Croisy A
NMR Biomed; 2000 Aug; 13(5):306-10. PubMed ID: 10960921
[TBL] [Abstract][Full Text] [Related]
17. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
18. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
19. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
20. The oral fluorouracil prodrugs.
Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
